// App-Quantinova.ai

: A phase I trial for the use of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) in the treatment of BCG-refractory nonmuscle invasive urothelial carcinoma of the bladder.

Researchers

Presenter

  • Guarionex Joel DeCastro

Principal Investigators

  • Wilson Sui

  • Jamie S. Pak

  • Corinne T. Abate-Shen

  • Shing Mirn Lee

  • Christopher B. Anderson

  • Dara Holder

  • James M. McKiernan

Medical Centers

  • Department of Urology, Columbia University Medical Center, New York, NY

  • Department of Pathology, Columbia University, New York, NY

  • Columbia University Medical Center Irving Cancer Research Center, New York, NY

  • Columbia University Medical Center, New York-Presbyterian Hospital, New York, NY

  • Univ. of Wisconsin-Madison, Madison, WI.

  • Columbia University Medical Center, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Cabazitaxel

  • Gemcitabine

  • Cisplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02202772

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved